Cobroxin, an Over-the-Counter (OTC) Pain Reliever Indicated for Treating Moderate to Severe (Stage 2) Chronic Pain, Will Be Available for Purchase in Walgreens by May 1, 2010
DELRAY BEACH, Fla., Mar 10, 2010 -- XenaCare Holdings, Inc. (OTCBB:XCHO), a company specializing in the marketing and retail distribution of consumer healthcare products, has announced today that its over-the-counter (OTC) pain reliever, Cobroxin, will be available for purchase in Walgreens by May 1, 2010. Walgreens is considered one of the nation's largest pharmacy chains with 7,162 drugstores located throughout the United States.
"As one of the largest and most well recognized pharmacy chains in North America, we are pleased that Walgreens has chosen to offer Cobroxin for sale in its drugstores throughout the United States," commented Frank Rizzo, President and CEO of XenaCare Holdings. "We look forward to working closely with Walgreens as we prepare for this launch and finalize our promotional strategy to support ongoing sales efforts by the retailer," he added.
Cobroxin is the first over-the-counter (OTC) pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain. Many other Stage 2 drugs require prescriptions, including Tylenol 3, Percocet, and Vicodin. Cobroxin is currently available as an Advanced Oral Spray for treating migraine headaches, neck aches, shoulder pain, cramps, lower back pain, and neuralgia and is also available as an Advanced Topical Gel for treating joint pain and pain associated with repetitive stress and arthritis.
Additional benefits to Cobroxin include:
-- All Natural
-- Non-Addictive
-- Non-Narcotic
-- Non-Opiate
-- Long Lasting
XenaCare Holdings was granted a license by Nutra Pharma Corporation (OTCBB:NPHC), the biotechnology company that developed and currently manufactures Cobroxin, to market and distribute Cobroxin within the United States.
About Nutra Pharma Corp.
Nutra Pharma Corporation (the "Company") operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases. The Company, through its subsidiaries, carries out basic drug discovery research and clinical development, and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. Nutra Pharma's wholly-owned drug discovery subsidiary, ReceptoPharm, is developing proprietary therapeutic protein products primarily for the prevention and treatment of viral and neurological diseases, including Multiple Sclerosis (MS), Adrenomyeloneuropathy (AMN), Human Immunodeficiency Virus (HIV), and pain in humans. Additionally, ReceptoPharm provides contract research services through its ISO class 5 and GMP certified facilities. The Company's wholly-owned medical devices subsidiary, Designer Diagnostics, engages in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases, such as Nontuberculous Mycobacteria (NTM). Nutra Pharma continues to identify intellectual property and companies in the biotechnology arena that it investigates about possibly acquiring or establish strategic partnerships with.
www.undiscoveredequities.net
www.nutrapharma.com
www.Cobroxin.com
Undiscovered Equities is currently offering a complimentary trial subscription.
To view our newsletter on a complimentary trial basis and take advantage of our other services go to www.undiscoveredequities.com and join our email list on our home page.
Sincerely,
Kevin McKnight
1-800-404-8982
Undiscovered Equities, Inc.
101 Plaza Real, Suite 212
Boca Raton, FL 33432
www.undiscoveredequities.com
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment